Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

61.74
+0.40000.65%
Post-market: 61.740.00000.00%19:05 EDT
Volume:628.86K
Turnover:38.70M
Market Cap:3.90B
PE:-14.23
High:61.96
Open:61.11
Low:60.93
Close:61.34
Loading ...

Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results

TIPRANKS
·
15 Apr

Rhythm Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
10 Apr

5 Stocks in Nasdaq ETF Fueling Index's Big Comeback Since 2008

Zacks
·
09 Apr

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study

Zacks
·
08 Apr

BUZZ-Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug

Reuters
·
08 Apr

Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating

MT Newswires Live
·
08 Apr

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?

Zacks
·
08 Apr

Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
08 Apr

Rhythm Pharmaceuticals Price Target Maintained With a $66.00/Share by Needham

Dow Jones
·
08 Apr

This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5%

GuruFocus.com
·
08 Apr

TD Cowen Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
08 Apr

Rhythm Pharmaceuticals upgraded to Buy from Neutral at BofA

TIPRANKS
·
08 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Janover, AMC Entertainment, U.S. Steel

Reuters
·
07 Apr

Rhythm Pharmaceuticals Shares up 4.8% After Drug for Rare Obesity Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
07 Apr

BRIEF-Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity

Reuters
·
07 Apr

Rhythm Pharmaceuticals' Obesity Treatment Meets Main Goal in Phase 3 Study, Shares Rise

MT Newswires Live
·
07 Apr

Rhythm Pharmaceuticals says Phase 3 TRANSCEND trial meets primary endpoint

TIPRANKS
·
07 Apr

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Reuters
·
07 Apr

Rhythm Pharmaceuticals Inc - No New Safety Signals Observed With Setmelanotide

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals Inc - Regulatory Submissions in U.S. and EU Expected Q3 2025

THOMSON REUTERS
·
07 Apr